VJHemOnc is committed to improving our service to you

SOHO 2020 | APR-246 in TP53 mutated MDS and AML

VJHemOnc is committed to improving our service to you

David Sallman

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, updates us on the use of APR-246, a p53 targeted therapy, evaluated with azacitidine in TP53 mutated MDS and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter